Peptide receptor imaging and therapy

Journal of Nuclear Medicine

Volumn 41, Issue 10, 2000, Pages 1704-1713

  Kwekkeboom, D ^a   Krenning, E P ^a   De Jong, M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

111In DTPA0 octreotide; 90Y DOTA0,Tyr3 octreotide; Peptide receptor radionuclide therapy; Somatostatin receptor scintigraphy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; OCTREOTIDE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID YTTRIUM 90]; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

CANCER STAGING; CARCINOID; GASTRINOMA; HUMAN; HYPOPHYSIS TUMOR; ISOTOPE LABELING; METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PARAGANGLIOMA; PRIORITY JOURNAL; RADIATION DOSE; RAT; RECEPTOR DENSITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR SCINTISCANNING;

HUMAN; INDIUM RADIOISOTOPES; NEOPLASMS; NEUROENDOCRINE TUMORS; OCTREOTIDE; OLIGOPEPTIDES; PENTETIC ACID; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YTTRIUM RADIOISOTOPES;

EID: 0033770117     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. The somatostatin receptor family
2. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas
3. The role of somatostatin and its analogues in the diagnosis and treatment of tumors
4. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to EGF-receptors
5. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas
6. 3] octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy
7. Indium- 111-diethylenetriamine-pentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes
8. 1]octreotide for detection of somatostatin receptor-positive tumors in rats
9. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue
10. Effect of dose and specific activity on tissue distribution of In-111-pentetreotide in rats
11. 1]octreotide in humans
12. Imaging with octreoscan: Haste makes waste
13. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: Safety, efficacy and impact on patient management
14. Human kidney as target for somatostatin: High affinity receptors in tubules and vasa recta
15. Specificity of somatostatin receptor scintigraphy: A prospective study and effects of false-positive localizations on management in patients with gastrinomas
16. Pituitary imaging using a labelled somatostatin analogue in acromegaly
17. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients
18. Receptor imaging in the diagnosis and treatment of pituitary tumors
19. Somatostatin receptor scintigraphy in pituitary adenomas: A somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo
20. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro
21. Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas
22. Use of radiolabeled somatostatin to localize islet cell tumors
23. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome
24. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study
25. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas
26. Radiologic diagnosis of neuroendocrine tumors
27. Localization of pancreatic endocrine tumors by endoscopic ultrasonography
28. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors
29. Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management
30. Somatostatin analogue scintigraphy in carcinoid tumors
31. Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers
32. 111In-DTPA-D-Phe1]-octreotide
33. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection
34. Treatment of the malignant carcinoid syndrome
35. Medical oncology considerations in patients with metastatic neuroendocrine carcinomas
36. Octreotide scintigraphy for the detection of paragangliomas
37. In vivo somatostatin receptor imaging in medullary thyroid carcinoma
38. Somatostatin receptor scintigraphy in medullary thyroid carcinoma
39. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings
40. Somatostatin receptor scintigraphy in non-medullary thyroid cancer
41. Somatostatin receptor expression in Hurthle cell cancer of the thyroid
42. Somatostatin analogue scintigraphy: A simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases
43. The value of octreotide scintigraphy in patients with lung cancer
44. 111In-DTPA octreotide scintigraphy
45. Somatostatin receptor scintigraphy in small-cell lung cancer: Results of a multicenter study
46. Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma
47. Cost-effectiveness analysis of somatostatin receptor scintigraphy
48. Somatostatin-receptor scintigraphy in primary breast cancer
49. Somatostatin analogue scintigraphy of malign ant lymphomas
50. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma
51. Indium-111 pentetreotide scintigraphy in malignant lymphomas
52. Somatostatin receptor scintigraphy in limited Hodgkin's disease: Clinical impact and relationship with risk categories
53. Sensitivity versus specificity in melanoma imaging using iodine- 123 iodobenzamide and indium-111 pentetreotide
54. 123I-Tyr-3-]-octreotide: The Rotterdam experience with more than 1000 patients
55. Expression of somatostatin receptors in childhood neuroblastoma
56. Somatostatin receptor scintigraphy: Its value in tumor localization in patients with the Cushing syndrome caused by ectopic cortictropin and/or CRH secretion
57. Somatostatin analogs for the localization and preoperative treatment of an ACTH-secreting bronchial carcinoid tumor
58. Localization of adrenocorticotropic hormone-secreting bronchial carcinoid tumor by somatostatin-receptor scintigraphy
59. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: Follow-up of 18 patients
60. Somatostatin receptor scintigraphy in central nervous system tumors: Role of blood-brain barrier permeability
61. Somatostatin receptor imaging in intracranial tumours
62. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors
63. Somatostatin analogue scintigraphy in granulomatous diseases
64. 1]-octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity?
65. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease
66. Octreotide scintigraphy in patients with sarcoidosis
67. Regulatory peptide receptors in goiters of the human thyroid
68. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy
69. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors
70. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide
71. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
72. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome
73. 111In-pentetreotide: Initial observations and future directions
74. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
75. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
76. Comparison of indium-111-DOTATOC and indium-111-DTPA-octreotide in the same patients: Biodistribution, kinetics, organ and tumor uptake
77. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide implications for internal radiotherapy with (90)Y-DOTATOC
78. 90Y-SMT487 (OctreoTher(TM)): A phase I study
79. Inhibition of renal uptake of indium-111 DTPA-octreotide in vivo
80. 3]octreotide eradicates experimental rat pancreatic CA20948 tumours